Table 3.
Pharmacokinetics of native FGF1 and FGF1ΔHBS following intraperitoneally treatment
| Parameters | FGF1 (n = 6) | FGF1△HBS (n = 6) |
|---|---|---|
| AUC(0-9h) (μg·h/L) | 267.70 ± 37.40 | 559.70 ± 104.50 ** |
| AUC(0-∞) (μg·h/L) | 279.20 ± 37.80 | 565.60 ± 105.60** |
| R_AUC (t/∞) | 95.80 ± 1.00 | 99.00 ± 0.40 |
| t1/2α (h) | 0.13 ± 0.07 | 0.40 ± 0.18 |
| t1/2z (h) | 2.00 ± 0.20 | 1.99 ± 0.56 |
| Tmax (h) | 1.25 ± 0.27 | 0.50 ± 0.00 ** |
| Vz (L/kg) | 5.24 ± 0.84 | 2.60 ± 0.70** |
| CLz (L/h·kg) | 1.82 ± 0.27 | 0.92 ± 0.22** |
| Cmax (μg/L) | 93.90 ± 28.70 | 367.00 ± 82.40** |
AUC, area-under-the-curve. t1/2α, absorption phase half-life. t1/2z, elimination phase half-life. Tmax, mean time to reach maximum serum concentration. Vz, volume of distribution. CLz, clearance. Cmax, maximum serum concentration. **P < 0.01 vs. FGF1.